Home/Filings/4/0001567619-22-021789
4//SEC Filing

Peppe Jennifer 4

Accession 0001567619-22-021789

CIK 0001623715other

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 4:27 PM ET

Size

28.9 KB

Accession

0001567619-22-021789

Insider Transaction Report

Form 4
Period: 2022-12-15
Peppe Jennifer
See Remarks
Transactions
  • Exercise/Conversion

    Stock Option (Right to buy)

    2022-12-1510,00081,500 total
    Exercise: $22.76Exp: 2031-11-16Common Stock (10,000 underlying)
  • Exercise/Conversion

    Common Stock

    2022-12-15$4.20/sh+12,400$52,080189,526 total
  • Exercise/Conversion

    Common Stock

    2022-12-15$2.10/sh+28,317$59,466177,126 total
  • Exercise/Conversion

    Common Stock

    2022-12-15$15.45/sh+2,145$33,140268,231 total
  • Exercise/Conversion

    Stock Option (Right to buy)

    2022-12-1528,31723,562 total
    Exercise: $2.10Exp: 2030-09-09Common Stock (28,317 underlying)
  • Exercise/Conversion

    Stock Option (Right to buy)

    2022-12-1558,5510 total
    Exercise: $2.52From: 2021-01-01Exp: 2027-03-28Common Stock (58,551 underlying)
  • Exercise/Conversion

    Common Stock

    2022-12-15$2.52/sh+58,551$147,549248,077 total
  • Exercise/Conversion

    Common Stock

    2022-12-15$1.52/sh+8,009$12,174256,086 total
  • Exercise/Conversion

    Common Stock

    2022-12-15$22.76/sh+10,000$227,600266,086 total
  • Sale

    Common Stock

    2022-12-15$35.80/sh119,422$4,275,236148,809 total
  • Exercise/Conversion

    Stock Option (Right to buy)

    2022-12-1512,40011,409 total
    Exercise: $4.20Exp: 2031-02-04Common Stock (12,400 underlying)
  • Exercise/Conversion

    Stock Option (Right to buy)

    2022-12-158,0092,729 total
    Exercise: $1.52Exp: 2029-04-09Common Stock (8,009 underlying)
  • Exercise/Conversion

    Stock Option (Right to buy)

    2022-12-152,145100,855 total
    Exercise: $15.45Exp: 2032-11-07Common Stock (2,145 underlying)
Footnotes (6)
  • [F1]The transaction was executed in multiple trades in prices ranging from $35.77 to $35.855, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F2]The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
  • [F3]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 12, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
  • [F4]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
  • [F5]25% of the shares subject to the option vest on the first anniversary measured from November 17, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  • [F6]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 8, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Documents

1 file

Issuer

Imago BioSciences, Inc.

CIK 0001623715

Entity typeother

Related Parties

1
  • filerCIK 0001861060

Filing Metadata

Form type
4
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 4:27 PM ET
Size
28.9 KB